Literature DB >> 22350072

Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation.

Janina Rahlff1, Maria Trusch, Friedrich Haag, Ulrike Bacher, Andrea Horst, Hartmut Schlüter, Mascha Binder.   

Abstract

Myeloma patients may develop oligoclonal immunoglobulins, so-called abnormal protein bands (APB), after stem cell transplantation. APB do not correspond to the patient's paraprotein and confer a good prognosis. We set out to investigate whether such APB represent a humoral anti-myeloma immune response by screening immunoglobulins of 15 myeloma patients after allogeneic stem cell transplantation and a control group of healthy donors for reactivity with myeloma protein extracts. While the immunoglobulins of healthy donors did not react with myeloma protein extracts, patient-derived immunoglobulins showed variable levels of interaction, depending on the presence of APB on immunofixation. Most commonly, we detected interactions with heat-shock proteins, followed by neutral alpha-glucosidase, alpha-enolase and vimentin, as well as proliferating cell nuclear antigen and MAGEA4. More than 80% of targets were upregulated in myeloma. Heat-shock protein 60 (HSP60) was subsequently evaluated as an exemplary antigen. We found that HSP60 was aberrantly displayed on the surface of primary myeloma cells. Indeed, patient-derived APB-containing immunoglobulins recognized surface HSP60 suggesting that this antigen becomes accessible to the immune system after aberrant membrane exposition. We conclude that immunoglobulin fractions with APB recognize recurrent myeloma antigens and that this humoral response may contribute to the more favorable prognosis in patients with APB.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350072     DOI: 10.1007/s00262-012-1220-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  Emergence of Oligoclonal Bands in Association with the use of Chemotherapy and Hematopoietic Stem Cell Transplantation.

Authors:  Chandramallika Paul; Sarit Chakraborty; Subhosmito Chakraborty
Journal:  Indian J Clin Biochem       Date:  2021-05-19

2.  Alterations in the ubiquitin proteasome system in persistent but not reversible proteinuric diseases.

Authors:  Maire Beeken; Maja T Lindenmeyer; Simone M Blattner; Victoria Radón; Jun Oh; Tobias N Meyer; Diana Hildebrand; Hartmut Schlüter; Anna T Reinicke; Jan-Hendrik Knop; Anuradha Vivekanandan-Giri; Silvia Münster; Marlies Sachs; Thorsten Wiech; Subramaniam Pennathur; Clemens D Cohen; Matthias Kretzler; Rolf A K Stahl; Catherine Meyer-Schwesinger
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

3.  Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.

Authors:  Marian F Schmitz; Henny G Otten; Laurens E Franssen; Suzanne van Dorp; Theo Strooisma; Henk M Lokhorst; Niels W C J van de Donk
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

4.  Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.

Authors:  Natalia Tovar; Carlos Fernández de Larrea; Juan I Aróstegui; Maria Teresa Cibeira; Laura Rosiñol; Montserrat Rovira; Montserrat Elena; Xavier Filella; Jordi Yagüe; Joan Bladé
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

5.  oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival.

Authors:  Manabu Fujisawa; Keisuke Seike; Kouta Fukumoto; Yasuhito Suehara; Masafumi Fukaya; Hiroki Sugihara; Masami Takeuchi; Kosei Matsue
Journal:  Cancer Sci       Date:  2014-10-09       Impact factor: 6.716

6.  High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers.

Authors:  Alessandra Rossi; Minna Voigtlaender; Hans Klose; Hartmut Schlüter; Gerhard Schön; Sonja Loges; Moreno Paolini; Carsten Bokemeyer; Martin Reck; Giulio Tarro; Mascha Binder
Journal:  J Oncol       Date:  2019-08-22       Impact factor: 4.375

7.  Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results.

Authors:  Gurmukh Singh
Journal:  J Clin Med Res       Date:  2017-07-01

8.  A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.

Authors:  Katja Klausz; Michael Cieker; Christian Kellner; Hans-Heinrich Oberg; Dieter Kabelitz; Thomas Valerius; Renate Burger; Martin Gramatzki; Matthias Peipp
Journal:  Oncotarget       Date:  2017-09-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.